Release
Photocure ASA - Share option grant
2026-07-29 21:48:38
Oslo, Norway, 29 July 2026 - Photocure ASA (the "Company") (OSE: PHO) has
granted share options to employees.
A total of 265,000 share options, equal to 0.98% of total shares issued in the
Company, were granted to the executive leadership team at an exercise price at
NOK 63,93 per share (the "ELT Options"). The exercise price is equal to the
weighted average share price 30 trading days before day of grant with an
additional premium of 10% on top of the calculated average price.
The ELT Options are granted in accordance with Photocure's long term incentive
program and the Company's guidelines for remuneration of senior executives (the
"Guidelines"), as approved by Photocure's annual general meeting held 26 June
2026. The share option program and properties of the options are further
described in the Guidelines.
The following ELT Options were granted to primary insiders:
· Daniel Schneider, President and Chief Executive Officer, 100,000
options
· Geoffrey Coy, Vice President and General Manager North America,
40,000 options
· Jane Healy, Vice President and General Manager Europe, 50,000
options
· Anders Neijber, Chief Medical Officer, Global Medical Affairs and
Clinical Development and R&D, 40,000 options
· Anja Gossens-Von Der Heidt, Head of Global Human Resources, 35,000
options
Primary insider notifications pursuant to the market abuse regulation article 19
are attached.
For further information, please contact:
Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: [email protected]
About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news
This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.
he\
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading\
Act.\